Change of Composition of the Telix Board of Directors
Melbourne (Australia) and Indianapolis, IN (USA) – 31 March 2022. Telix announces that Tiffany Olson has been appointed to the Board, as a U.S.-based independent Non-Executive Director.
Telix is pleased to announce that Tiffany Olson has been appointed to the Board, as a U.S.-based independent Non-Executive Director.
Ms. Olson brings a depth of experience in commercialisation and corporate strategy in oncology, including in the radiopharmaceutical sector. Her most recent executive role was with Cardinal Health, the largest provider of radiopharmaceuticals in the United States, where she was President of Cardinal Health Nuclear & Precision Health Solutions overseeing Cardinal’s radiopharmaceutical manufacturing and nuclear pharmacy network. During her eight-year tenure in this role she led a major business transformation which led to increased market share and profit growth. Prior to her role at Cardinal Health, Ms. Olson served as President of NaviMed and in executive roles at Eli Lilly and Roche, where she attained the position of President and CEO of Roche Diagnostics Corporation.
Ms. Olson currently serves as a Board member for Castle Biosciences; ERF, Education & Research Foundation for Nuclear Medicine & Molecular Imaging; and is on the Langham Logistics Advisory Board. Tiffany holds a Bachelor of Business from the University of Minnesota and an MBA from St. Thomas University in Minnesota. Ms. Olson has received many recognitions for her work in healthcare. She was named one of the “10 Best Women Leaders of 2020” by Industry Era and was the first woman to receive the Life Science Alley Luminary Award.
Telix Chairman, Kevin McCann AO said, “Tiffany is an outstanding addition to our Board of Directors. Her appointment supports our governance principles and continues to ensure that the Board has the right mix of skills, diversity and independence. An accomplished leader with a strong track record in commercialisation and building large-scale businesses in the radiopharmaceutical sector, Tiffany’s deep operational understanding of radiopharmaceutical manufacturing, distribution networks and customers will be invaluable as Telix rolls out its first commercial product.”
Ms. Olson added, “I am delighted to join the Board of Telix at this exciting phase in the Company’s journey. I look forward to working with the Telix team to leverage my experience and networks to guide the Company through the next phase of its trajectory, in particular the launch of Illuccix and the commercialization of follow-on diagnostic and therapeutic products.”
Ms. Olson will join Telix as an independent Non-Executive Director and will be a member of the Audit and Risk Committee. Her appointment is effective 31 March 2022. Ms. Olson will stand for re-election as a Non-Executive Director at Telix’s Annual General Meeting, to be held on 18 May 2022.
Telix advises that Mr. Oliver Buck will retire from the Board at the Company’s 2022 Annual General Meeting. Having served on the Telix Board since 16 January 2017, Mr. Buck has taken the decision to retire from the Board due to the increasing time commitment associated with his portfolio of global Board and advisory roles.
“On behalf of the Board and the Company I sincerely thank Oliver for his five years of service to Telix. His technical expertise and industry knowledge has been essential during Telix’s early, formative years, and we remain very grateful for his contributions to the Company” concluded Kevin McCann.
To read the full ASX disclosure please click here.
To return to Telix’s homepage please click here.